Oculocutaneous tyrosinemia

Search Trials
Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin
Status:
Completed
Last Changed:
Mar 15, 2017
First Changed:
Apr 25, 2016
Disease(s):
Hereditary Tyrosinemia, Type I
Intervention(s):
NitisinoneNitisinone 10 mg Tablet High CompritolOrfadin
Bio Equivalency 20 Mgm Orfadin and 20 Mgm of Nitisonine
Status:
Unknown status
Last Changed:
Oct 3, 2019
First Changed:
Oct 3, 2019
Disease(s):
Hereditary Tyrosinemia, Type I
Intervention(s):
NitisinoneOrfadin
Taste and Palatability of Orfadin Suspension
Status:
Completed
Last Changed:
Nov 6, 2014
First Changed:
Nov 28, 2012
Disease(s):
Hereditary Tyrosinemia, Type I
Intervention(s):
Nitisinone
Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 (BioTyrosin)
Status:
Active, not recruiting
Last Changed:
May 18, 2021
First Changed:
Sep 15, 2017
Disease(s):
Tyrosinosis
Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Nitisinone in HT-1
Status:
Completed
Last Changed:
Nov 11, 2015
First Changed:
Dec 23, 2014
Disease(s):
Hereditary Tyrosinemia, Type I
Intervention(s):
Nitisinone

Connect. Empower. Inspire.